Sunday, March 30, 2014 11:03:36 AM
I don't know very much about the approval process of an approved drug for other uses (assuming it will be approved for NASH). Is it even needed? So far, most of the projections of value (PPS) I've seen have been centered around NASH. In my opinion, I don't think GR-MD-02's usefulness will be limited to just NASH. We already have the melanoma study in the works. Remember that NASH is the second greatest cause of liver fibrosis and cirrhosis in the U.S. If GR-MD-02 is effective in treating alcoholic hepatitis and fibrosis/cirrhosis (number one cause), well the market for the drug may have just doubled. Efficacy has already been proven in animal studies (I don't know how many different species) but there may also be uses for treatment of fibrosis in veterinary medicine (I'm thinking mainly renal disease--very common in pets these days). I guess I'm pointing this out because I've been thinking a lot about when to "get out" of GALT. It would be tempting to me to take whatever profits present themselves early on but I'd be afraid of missing out on later potential. On the other hand, I don't know how a buyout would affect profits. I have NO experience in this. Is it generally better to wait for a buyout or sell just before? Seems like a tricky thing to judge.
Though I am envious of many of you with large positions I am also respectful of the insight that led you to it. So I would like to give a quick thanks to all of you on this forum. I follow a few other stocks on ihub (though I have since sold them to use the cash for GALT purchases) and this is by far the best for minimal silliness, and clear communication. Looking forward to the next few days. I figure if Chipotle stock can reach 600 and it's just a hip restaurant chain, why not a life-saving drug with the capacity to end so much suffering.
Best of luck to all of you!
Recent GALT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/20/2024 05:55:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:55:18 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 11:50:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 05:50:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:55:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:52:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:51:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:50:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:48:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:47:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:46:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:44:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:43:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:40:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 04:23:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 01:07:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 01:41:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 04:42:44 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 09:50:50 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/01/2023 09:38:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 01:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 10:19:22 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/13/2023 02:21:40 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM